Armando Andres Roca Suarez, Marie-Laure Plissonnier, Xavier Grand, Maud Michelet, Guillaume Giraud, Maria Saez-Palma, Anaëlle Dubois, Sarah Heintz, Audrey Diederichs, Nicolaas Van Renne, Thomas Vanwolleghem, Stephane Daffis, Li Li, Nikita Kolhatkar, Yao-Chun Hsu, Jeffrey J Wallin, Audrey H Lau, Simon P Fletcher, Michel Rivoire, Massimo Levrero, Barbara Testoni, Fabien Zoulim
OBJECTIVE: Achieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory agents. In this context, the toll-like receptor 8 (TLR8) agonist selgantolimod (SLGN) has been investigated in preclinical models and clinical trials for chronic hepatitis B (CHB). However, little is known regarding its action on immune effectors within the liver. Our aim was to characterise the transcriptomic changes and intercellular communication events induced by SLGN in the hepatic microenvironment...
May 2, 2024: Gut